Skip to main content
SpringerLink
Log in

Atypical Antipsychotics in Major Depressive Disorder

  • Chapter
  • First Online:
Understanding Depression

Abstract

Depression represents one of the most invalidating and widespread diseases in the Western countries. Depressive episodes could manifest both in unipolar and bipolar mood disorders, hence, not facilitating the choice of the better psychopharmacological treatment. Antidepressants represent the first-line choice in the treatment of a depressive episode within a major depressive disorder (MDD). However, as approximately 10–15% of patients do not adequately respond to a pharmacological therapy, the treatment-resistant depression (TRD) may benefit by atypical antipsychotics as monotherapy or adjunctive therapy. Furthermore, as recently introduced in the Diagnostic and Statistical Manual-5th edition (DSM-5), depressive episodes may occur in association with mixed states, which could justify the prescription of an atypical antipsychotic as add-on therapy. The present chapter aims at reviewing literature and data evaluating the efficacy and effectiveness of prescribing atypical antipsychotics in MDD.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology. 2009;205(1):119–28.

    Article  CAS  Google Scholar 

  • Agarwal SM, Rao NP, Venkatasubramanian G, Behere RV, Varambally S, Gangadhar BN. Successful treatment of atypical depression with amisulpride: a case report. Asian J Psychiatr. 2012;5(4):362.

    Article  Google Scholar 

  • American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington: American Psychiatric Association; 2013.

    Book  Google Scholar 

  • Amore M, Jori MC, AMISERT Investigators. Faster response on amisulpride 50 mg versus sertraline 50-100 mg in patients with dysthymia or double depression: a randomized, double-blind, parallel group study. Int Clin Psychopharmacol. 2001;16(6):317–24.

    Article  CAS  Google Scholar 

  • Arbaizar B, Dierssen-Sotos T, Gómez-Acebo I, Llorca J. Aripiprazole in major depression and mania: meta-analyses of randomized placebo-controlled trials. Gen Hosp Psychiatry. 2009;31(5):478–83.

    Article  Google Scholar 

  • Azorin JM, Sapin C, Weiller E. Effect of asenapine on manic and depressive symptoms in bipolar I patients with mixed episodes: results from post hoc analyses. J Affect Disord. 2013;145(1):62–9.

    Article  CAS  Google Scholar 

  • Banov MD, Zarate CA Jr, Tohen M, Scialabba D, Wines JD Jr, Kolbrener M, Kim JW, Cole JO. Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. J Clin Psychiatry. 1994;55:295–300.

    CAS  PubMed  Google Scholar 

  • Berk M, Tiller JW, Zhao J, Yatham LN, Malhi GS, Weiller E. Effects of asenapine in bipolar I patients meeting proxy criteria for moderate-to-severe mixed major depressive episodes: a post hoc analysis. J Clin Psychiatry. 2015;76:728–34.

    Article  Google Scholar 

  • Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, Khan A. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(6):843–53.

    Article  CAS  Google Scholar 

  • Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, Carson WH, Adson D, Taylor L, Hazel J, Marcus RN. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr. 2009;14(4):197–206.

    Article  Google Scholar 

  • Björkholm C, Frånberg O, Malmerfelt A, Marcus MM, Konradsson-Geuken Å, Schilström B, Jardemark K, Svensson TH. Adjunctive treatment with asenapine augments the escitalopram-induced effects on monoaminergic outflow and glutamatergic neurotransmission in the medial prefrontal cortex of the rat. Int J Neuropsychopharmacol. 2014;18(3): pyu068.

    Article  Google Scholar 

  • Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, de Girolamo G, de Graaf R, Demyttenaere K, Hu C, Iwata N, Karam AN, Kaur J, Kostyuchenko S, Lépine JP, Levinson D, Matschinger H, Mora ME, Browne MO, Posada-Villa J, Viana MC, Williams DR, Kessler RC. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011;9:90.

    Article  Google Scholar 

  • Carta MG, Zairo F, Mellino G, et al. An open label follow-up study on amisulpride in the add-on treatment of bipolar I patients. Clin Pract Epidemiol Ment Health. 2006;2:19.

    Article  Google Scholar 

  • Carvalho AF, Nunes-Neto PR, Cavalcante JL, Oliveira Lima MC. Amisulpride augmentation after the failure of citalopram for depression: a case report. J Clin Pharm Ther. 2007;32(1):97–9.

    Article  CAS  Google Scholar 

  • Cassano G, Jori M. Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: a randomized, double-blind, parallel group study. Int Clin Psychopharmacol. 2002;17:27–2.

    Article  CAS  Google Scholar 

  • Chen J, Gao K, Kemp DE. Second-generation antipsychotics in major depressive disorder: update and clinical perspective. Curr Opin Psychiatry. 2011;24(1):10–7.

    Article  Google Scholar 

  • Citrome L. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic—what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2015;69(9):978–97.

    Article  CAS  Google Scholar 

  • Davis LL, Ota A, Perry P, Tsuneyoshi K, Weiller E, Baker R. Adjunctive brexpiprazole (OPC-34712) in patients with major depressive disorder and anxiety symptoms: an exploratory study. Biol Psychiatry. 2015;77(9 Suppl 1):S66.

    Google Scholar 

  • De Berardis D, Orsolini L, Iasevoli F, Prinzivalli E, de Bartolomeis A, Serroni N, Mazza M, Valchera A, Fornaro M, Vecchiotti R, Carano A, Sepede G, Vellante F, Matarazzo I, Pompili M, Perna G, Conti C, Segura-García C, Martinotti G, Di Giannantonio M. The novel antipsychotic cariprazine (RGH-188): state-of-the-art in the treatment of psychiatric disorders. Curr Pharm Des. 2016;22(33):5144–62.

    Article  Google Scholar 

  • Delcourte S, Abrial E, Etiévant A, Rovera R, Arnt J, Didriksen M, Haddjeri N. Asenapine modulates mood-related behaviors and 5-HT(1A/7) receptors-mediated neurotransmission. CNS Neurosci Ther. 2017;23(6):518–25.

    Article  CAS  Google Scholar 

  • Dimitrakopoulos S, Konstantakopoulos G. Pharmacological agents under research for the maintenance treatment in bipolar disorder. Psychiatriki. 2015;26(3):169–80.

    CAS  PubMed  Google Scholar 

  • FDA. Advisory Committee Documentation: Seroquel XR® (quetiapine fumarate) for major depressive disorder (MDD) or generalized anxiety disorder (GAD). 2009.

    Google Scholar 

  • Fornaro M, Stubbs B, De Berardis D, Perna G, Valchera A, Veronese N, Solmi M, Ganança L. Atypical antipsychotics in the treatment of acute bipolar depression with mixed features: a systematic review and exploratory meta-analysis of placebo-controlled clinical trials. Int J Mol Sci. 2016;17(2):241.

    Article  Google Scholar 

  • Frakenburg FR. Clozapine and bipolar disorder. J Clin Psychopharmacol. 1993;13:289–90.

    Article  CAS  Google Scholar 

  • Gigante AD, Lafer B, Yatham LN. Long-acting injectable antipsychotics for the maintenance treatment of bipolar disorder. CNS Drugs. 2012;26(5):403–20.

    Article  CAS  Google Scholar 

  • Greenberg WM, Citrome L. Pharmacokinetics and pharmacodynamics of lurasidone hydrochloride, a second-generation antipsychotic: a systematic review of the published literature. Clin Pharmacokinet. 2017;56(5):493–503.

    Article  CAS  Google Scholar 

  • Gruenberg AM, Goldstein RD, Pincus HA. Classification of depression: research and diagnostic criteria: DSM-IV and ICD-10. Biology of depression: from novel insights to therapeutic strategies. Weinheim: Wiley; 2008.

    Google Scholar 

  • Hardoy MC, Carta MG. Strategy to accelerate or augment the antidepressant response and for an early onset of SSRI activity. Adjunctive amisulpride to fluvoxamine in major depressive disorder. Clin Pract Epidemiol Ment Health. 2010;6:1–3.

    Article  Google Scholar 

  • Hasnain M, Vieweg WV, Hollett B. Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians. Postgrad Med. 2012;124(4):154–67.

    Article  Google Scholar 

  • Heo JY, Jeon HJ, Fava M, Mischoulon D, Baer L, Clain A, Doorley J, Pisoni A, Papakostas GI. Efficacy of ziprasidone monotherapy in patients with anxious depression: a 12-week, randomized, double-blind, placebo-controlled, sequential-parallel comparison trial. J Psychiatr Res. 2015;62:56–61.

    Article  Google Scholar 

  • Ionescu DF, Shelton RC, Baer L, Meade KH, Swee MB, Fava M, Papakostas GI. Ziprasidone augmentation for anxious depression. Int Clin Psychopharmacol. 2016;31(6):341–6.

    Article  Google Scholar 

  • Jarema M. Atypical antipsychotics in the treatment of mood disorders. Curr Opin Psychiatry. 2007;20(1):23–9.

    Article  Google Scholar 

  • Joffe RT, Levitt AJ, Sokolov ST. Augmentation strategies: focus on anxiolytics. J Clin Psychiatry. 1996;57(Suppl 7):25–31.

    Google Scholar 

  • Keitner GI, Garlow SJ, Ryan CE, Ninan PT, Solomon DA, Nemeroff CB, Keller MB. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res. 2009;43(3):205–14.

    Article  Google Scholar 

  • Keller MC, Nesse RM. The evolutionary significance of depressive symptoms: different adverse situations lead to different depressive symptom patterns. J Pers Soc Psychol. 2006;91:316–30.

    Article  Google Scholar 

  • Khan A. Current evidence for aripiprazole as augmentation therapy in major depressive disorder. Expert Rev Neurother. 2008;8(10):1435–47.

    Article  CAS  Google Scholar 

  • Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S. Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev. 2010;12:CD008121.

    Google Scholar 

  • Krystal A, Mittoux A, Meisels P, Baker R. Adjunctive brexpiprazole (OPC-34712) in patients with major depressive disorder and sleep disturbances: an exploratory study. Biol Psychiatry. 2015;77(9 Suppl 1):S64–5.

    Google Scholar 

  • Lecrubier Y, Boyer P, Turjanski S, Rein W. Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group. J Affect Disord. 1997;43(2):95–103.

    Article  CAS  Google Scholar 

  • Li XB, Tang YL, Wang CY, de Leon J. Clozapine for treatment-resistant bipolar disorder: a systematic review. Bipolar Disord. 2015;17(3):235–47.

    Article  CAS  Google Scholar 

  • Lin CY, Tsai GE, Wang HS, Wu YH, Chiou CC, Wu VY, Lane HY. Effectiveness of aripiprazole, olanzapine, quetiapine, and risperidone augmentation treatment for major depressive disorder: a nationwide population-based study. J Clin Psychiatry. 2014;75(9):e924–31.

    Article  CAS  Google Scholar 

  • Loebel A, Cucchiaro J, Silva R, Kroger H, Sarma K, Xu J, Calabrese JR. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171:160–8.

    Article  Google Scholar 

  • Luan S, Wan H, Wang S, Li H, Zhang B. Efficacy and safety of olanzapine/fluoxetine combination in the treatment of treatment-resistant depression: a meta-analysis of randomized controlled trials. Neuropsychiatr Dis Treat. 2017;13:609–20.

    Article  Google Scholar 

  • Maeda K, Lerdrup L, Suqino H, et al. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;351(3):686–7.

    Article  Google Scholar 

  • Maher AR, Theodore G. Summary of the comparative effectiveness review on off-label use of atypical antipsychotics. J Manag Care Pharm. 2012;18(5 Suppl B):S1–S20.

    Google Scholar 

  • Mahmoud RA, Pandina GJ, Turkoz I, Kosik-Gonzalez C, Canuso CM, Kujawa MJ, Gharabawi-Garibaldi GM. Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann Intern Med. 2007;147(9):593–602.

    Article  Google Scholar 

  • Maneeton N, Maneeton B, Srisurapanont M, Martin SD. Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials. BMC Psychiatry. 2012;12(1):160.

    Article  CAS  Google Scholar 

  • Marazziti D, Piccinni A, Baroni S, Mungai F, Presta S, Mucci F, Dell'Osso L. Current trends on antipsychotics: focus on asenapine. Curr Med Chem. 2016;23(21):2204–16.

    Article  CAS  Google Scholar 

  • Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, Trivedi MH, Thase ME, Berman RM. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28(2):156–65.

    Article  CAS  Google Scholar 

  • McDonagh M, Peterson K, Carson S, Fu R, Thakurta S. Drug class review: atypical antipsychotic drugs: final update 3 report [Internet]. Portland: Oregon Health & Science University; 2010.

    Google Scholar 

  • McElroy SL, Dessain EC, Pope HG Jr, Cole JO, Keck PE Jr, Frankenberg FR, Aizley HG, O'Brien S. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clin Psychiatry. 1991;52:411–4.

    CAS  PubMed  Google Scholar 

  • McIntyre RS, Muzina DJ, Adams A, Lourenco MT, Law CW, Soczynska JK, Woldeyohannes HO, Nathanson J, Kennedy SH. Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials. Expert Opin Pharmacother. 2009;10(18):3061–75.

    Article  CAS  Google Scholar 

  • McIntyre RS, Weiller E, Zhang P, Weiss C. Brexpiprazole as adjunctive treatment of major depressive disorder with anxious distress: results from a post-hoc analysis of two randomized controlled trials. J Affect Disord. 2016;201:116–23.

    Article  CAS  Google Scholar 

  • Menard F, Fava M, Davidsen CK, Baker RA. Adjunctive brexpiprazole (OPC-34712) in patients with major depressive disorder and irritability: an exploratory study. Biol Psychiatry. 2015;77(9 suppl 1):S65.

    Google Scholar 

  • Montgomery SA. Dopaminergic deficit and the role of amisulpride in the treatment of mood disorders. Int Clin Psychopharmacol. 2002;17(Suppl 4):S9–S15. discussion S16–S17

    PubMed  Google Scholar 

  • Monti JM. The effect of second-generation antipsychotic drugs on sleep parameters in patients with unipolar or bipolar disorder. Sleep Med. 2016;23:89–96.

    Article  Google Scholar 

  • Muneer A. Pharmacotherapy of acute bipolar depression in adults: an evidence based approach. Korean J Fam Med. 2016;37(3):137–48.

    Article  Google Scholar 

  • Nelson JC, Thase ME, Bellocchio EE, Rollin LM, Eudicone JM, McQuade RD, Marcus RN, Berman RM, Baker RA. Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy. Int Clin Psychopharmacol. 2012;27(3):125–33.

    Article  Google Scholar 

  • Orsolini L, Tomasetti C, Valchera A, Vecchiotti R, Matarazzo I, Vellante F, Iasevoli F, Buonaguro EF, Fornaro M, Fiengo AL, Martinotti G, Mazza M, Perna G, Carano A, De Bartolomeis A, Di Giannantonio M, De Berardis D. An update of safety of clinically used atypical antipsychotics. Expert Opin Drug Saf. 2016;15(10):1329–47.

    Article  CAS  Google Scholar 

  • Pae CU, Forbes A, Patkar AA. Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. CNS Drugs. 2011;25(2):109–27.

    Article  CAS  Google Scholar 

  • Papakostas GI. Atypical antipsychotic agents for treatment-resistant major depressive disorder. Essent Psychopharmacol. 2005;6(4):209–20.

    PubMed  Google Scholar 

  • Papakostas GI, Petersen TJ, Nierenberg AA, Murakami JL, Alpert JE, Rosenbaum JF, Fava M. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry. 2004;65:217–21.

    Article  CAS  Google Scholar 

  • Papakostas GI, Fava M, Baer L, Swee MB, Jaeger A, Bobo WV, Shelton RC. Ziprasidone augmentation of escitalopram for major depressive disorder: efficacy results from a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2015;172(12):1251–8.

    Article  Google Scholar 

  • Parikh NB, Robinson DM, Clayton AH. Clinical role of brexpiprazole in depression and schizophrenia. Ther Clin Risk Manag. 2017;13:299–306.

    Article  Google Scholar 

  • Pawar GR, Agrawal RP, Phadnis P, Paliwal A, Vyas S, Solanki P. Evaluation of antidepressant like property of amisulpride per se and its comparison with fluoxetine and olanzapine using forced swimming test in albino mice. Acta Pol Pharm. 2009;66(3):327–31.

    CAS  PubMed  Google Scholar 

  • Politis AM, Papadimitriou GN, Theleritis CG, Psarros C, Soldatos CR. Combination therapy with amisulpride and antidepressants: clinical observations in case series of elderly patients with psychotic depression. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(5):1227–30.

    Article  CAS  Google Scholar 

  • Rexulti® (brexpiprazole) [full prescribing information]. 2015. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205422s000lbl.pdf. Accessed 18 Jan 2016.

  • Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors, focus on newer generation compounds. Life. Science. 2000;68(1):29–39.

    CAS  Google Scholar 

  • Rogóż Z. Combined treatment with atypical antipsychotics and antidepressants in treatment-resistant depression: preclinical and clinical efficacy. Pharmacol Rep. 2013;65(6):1535–44.

    Article  Google Scholar 

  • Sanford M. Quetiapine extended release: adjunctive treatment in major depressive disorder. CNS Drugs. 2011;25(9):803–13.

    Article  CAS  Google Scholar 

  • Schmidt AW, Lebel A, Howard HR Jr, Zom SH. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol. 2001;425:197–201.

    Article  CAS  Google Scholar 

  • Shelton RC, Papakostas GI. Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. Acta Psychiatr Scand. 2008;117(4):253–9.

    Article  CAS  Google Scholar 

  • Smeraldi E. Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study. J Affect Disord. 1998;48(1):47–56.

    Article  CAS  Google Scholar 

  • Souery D, Amsterdam J, de Montigny C, Lecrubier Y, Montgomery S, Lipp O, Racagni G, Zohar J, Mendlewicz J. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol. 1999;9(1–2):83–91.

    Article  CAS  Google Scholar 

  • Stahl SM. Mechanism of action of brexpiprazole: comparison with aripiprazole. CNS Spectr. 2016;21(1):1–6.

    Article  Google Scholar 

  • Stahl SM, Morrissette DA, Faedda G, Fava M, Goldberg JF, Keck PE, Lee Y, Malhi G, Marangoni C, McElroy SL, Ostacher M, Rosenblat JD, Solé E, Suppes T, Takeshim M, Thase ME, Vieta E, Young A, Zimmerman M, McIntyre RS. Guidelines for the recognition and management of mixed depression. CNS Spectr. 2017;22(2):203–19.

    Article  Google Scholar 

  • Szegedi A, Zhao J, van Willigenburg A, Nations KR, Mackle M, Panagides J. Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials. BMC Psychiatry. 2011;11:101.

    Article  CAS  Google Scholar 

  • Tarazi FI, Stahl SM. Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opin Pharmacother. 2012;13(13):1911–22.

    Article  CAS  Google Scholar 

  • Tatsumi M, Jansen K, Blakely RD, Richelson E. Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol. 1999;368(2–3):277–83.

    Article  CAS  Google Scholar 

  • Thase ME, Demyttenaere K, Earley WR, Gustafsson U, Udd M, Eriksson H. Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression. Depress Anxiety. 2012;29(7):574–86.

    Article  CAS  Google Scholar 

  • Thase ME, Youakim JM, Skuban A, Hobart M, Augustine C, Zhang P, McQuade RD, Carson WH, Nyilas M, Sanchez R, Eriksson H. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry. 2015a;76(9):1224–31.

    Article  Google Scholar 

  • Thase ME, Youakim JM, Skuban A, Hobart M, Zhang P, McQuade RD, Nyilas M, Carson WH, Sanchez R, Eriksson H. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry. 2015b;76(9):1232–40.

    Article  Google Scholar 

  • Torta R, Berra C, Binaschi L, Borio R. Amisulpride in the short-term treatment of depressive and physical symptoms in cancer patients during chemotherapies. Support Care Cancer. 2007;15(5):539–46.

    Article  Google Scholar 

  • Ward MP, Irazoqui PP. Evolving refractory major depressive disorder diagnostic and treatment paradigms: toward closed-loop therapeutics. Front Neuroeng. 2010;3:7.

    PubMed  PubMed Central  Google Scholar 

  • Weber J, Lyseng-Williamson KA, Scott LJ. Aripiprazole: in major depressive disorder. CNS Drugs. 2008;22(10):807–13.

    Article  CAS  Google Scholar 

  • Weisler RH, Montgomery SA, Earley WR, Szamosi J, Lazarus A. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies. Int Clin Psychopharmacol. 2012;27(1):27–39.

    Article  Google Scholar 

  • Yan JX. A double-blind clinical trial of add-on clozapine in the treatment of treatment-resistant depression. Clin J Psychol Med. 2001;11:170–1.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hatfield, Hatfield, Herts, UK

    Laura Orsolini

  2. Polyedra Research Group, Teramo, Italy

    Laura Orsolini, Federica Vellante & Alessandro Valchera

  3. Department of Neurosciences and Imaging, University “G. d’Annunzio”, Chieti, Italy

    Federica Vellante, Giovanni Martinotti, Massimo Di Giannantonio & Domenico De Berardis

  4. Villa S. Giuseppe, Hospital Hermanas Hospitalarias, Ascoli Piceno, Italy

    Alessandro Valchera

  5. Laboratory of Molecular Psychiatry and Psychopharmacotherapeutics, Unit of Psychiatry, Department of Neuroscience, University School of Medicine “Federico II”, Naples, Italy

    Michele Fornaro

  6. Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital “Madonna Del Soccorso”, NHS, San Benedetto del Tronto, Ascoli Piceno, Italy

    Alessandro Carano

  7. Department of Neurosciences, Mental Health and Sensory Organs, Suicide Prevention Center, Sant’Andrea Hospital, Sapienza University of Rome, Rome, Italy

    Maurizio Pompili

  8. Department of Clinical Neurosciences, Villa San Benedetto Menni, Hermanas Hospitalarias, FoRiPsi, Albese con Cassano, Como, Italy

    Giampaolo Perna

  9. Department of Psychiatry and Neuropsychology, University of Maastricht, Maastricht, The Netherlands

    Giampaolo Perna

  10. Department of Psychiatry and Behavioral Sciences, Leonard Miller School of Medicine, University of Miami, Miami, FL, USA

    Giampaolo Perna

  11. Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), Section of Psychiatry, University of Genoa, IRCCS San Martino, Genoa, Italy

    Gianluca Serafini

  12. Institute of Psychiatry and Psychology, Fondazione Policlinico Universitario “A. Gemelli”, Università Cattolica del Sacro Cuore, Rome, Italy

    Marco Di Nicola & Domenico De Berardis

  13. National Health Service, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital “G. Mazzini”, Teramo, Italy

    Domenico De Berardis

Authors
  1. Laura Orsolini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Federica Vellante
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alessandro Valchera
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michele Fornaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alessandro Carano
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maurizio Pompili
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Giampaolo Perna
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Gianluca Serafini
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Marco Di Nicola
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Giovanni Martinotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Massimo Di Giannantonio
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Domenico De Berardis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Domenico De Berardis .

Editor information

Editors and Affiliations

  1. College of Medicine, Korea University, Kyonggi-do, Korea (Republic of)

    Yong-Ku Kim

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Singapore Pte Ltd.

About this chapter

Cite this chapter

Orsolini, L. et al. (2018). Atypical Antipsychotics in Major Depressive Disorder. In: Kim, YK. (eds) Understanding Depression. Springer, Singapore. https://doi.org/10.1007/978-981-10-6577-4_18

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-6577-4_18

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-6576-7

  • Online ISBN: 978-981-10-6577-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation